These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 9331008

  • 1. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension.
    Heuer HJ, Schöndorfer G, Högemann AM.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S55-6. PubMed ID: 9331008
    [No Abstract] [Full Text] [Related]

  • 2. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension.
    Andersson OK, Neldam S.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S63-4. PubMed ID: 9331011
    [No Abstract] [Full Text] [Related]

  • 3. Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
    Franke H.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S61-2. PubMed ID: 9331010
    [No Abstract] [Full Text] [Related]

  • 4. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G, Fuchs W.
    Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
    [Abstract] [Full Text] [Related]

  • 5. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension.
    Zanchetti A, Omboni S, Di Biagio C.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S57-9. PubMed ID: 9331009
    [No Abstract] [Full Text] [Related]

  • 6. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT, O'Kane KP, Jonker J, Roth J.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [Abstract] [Full Text] [Related]

  • 7. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP, Nisse-Durgeat S, Mouret S, Asmar R, Mallion JM.
    Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H, Ogihara T, Miyata Y, Sasai K, Totsuka N.
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [Abstract] [Full Text] [Related]

  • 9. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension.
    Sever P, Holzgreve H.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S69-73. PubMed ID: 9331014
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of candesartan cilexetil in special patient groups.
    Trenkwalder P.
    Blood Press Suppl; 2000 Sep; 1():27-30. PubMed ID: 11059633
    [Abstract] [Full Text] [Related]

  • 11. Reducing cardiovascular morbidity and mortality in the elderly.
    Trenkwalder P.
    Blood Press Suppl; 2000 Sep; 1():40-3. PubMed ID: 11059636
    [Abstract] [Full Text] [Related]

  • 12. Achieving quality 24-h blood pressure control with candesartan cilexetil.
    Meredith P.
    Blood Press Suppl; 2000 Sep; 1():23-6. PubMed ID: 11059632
    [Abstract] [Full Text] [Related]

  • 13. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [Abstract] [Full Text] [Related]

  • 14. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F.
    Blood Press Suppl; 2000 Sep; 1():36-9. PubMed ID: 11059635
    [Abstract] [Full Text] [Related]

  • 15. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
    Elmfeldt D, George M, Hübner R, Olofsson B.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S49-53. PubMed ID: 9331007
    [Abstract] [Full Text] [Related]

  • 16. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
    Ogihara T, Arakawa K.
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
    [Abstract] [Full Text] [Related]

  • 17. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P, Reismann J, Pohlmeyer H, Düsing R.
    Dtsch Med Wochenschr; 2001 May 11; 126(19):547-50. PubMed ID: 11402910
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial.
    Association of Black Cardiologists (ABC) Candesartan Study Group.
    Heart Dis; 2000 May 11; 2(6):392-9. PubMed ID: 11728289
    [Abstract] [Full Text] [Related]

  • 19. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS.
    J Hypertens Suppl; 1997 Dec 11; 15(6):S9-12. PubMed ID: 9493121
    [Abstract] [Full Text] [Related]

  • 20. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS.
    Blood Press Suppl; 2000 Dec 11; 1():19-22. PubMed ID: 11059631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.